Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Voriconazole Dosing for Resistant Tinea Corporis and Cruris
NCT06680544Phase 2Not yet recruiting
- Sponsor
- Sheikh Zayed Medical College
- Start
- Nov 2024
- Primary completion
- Mar 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised trial of voriconazole in tinea corporis and Tinea cruris (TC) (2 arms), sponsored by Sheikh Zayed Medical College. Primary endpoint: Efficacy of oral voriconazole at Day 28. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
voriconazole
03
Conditions
tinea corporisTinea cruris (TC)
Beyond the preview
Go deeper on NCT06680544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06680544.